deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03502616

Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)

Sponsor: Pfizer

Conditions Ankylosing Spondylitis
Interventions Tofacitinib
Updated 27 times since 2018 Last updated: Aug 19, 2021 Started: Jun 7, 2018 Primary completion: Dec 19, 2019 Completion: Aug 20, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03502616, this PHASE3 trial focuses on Ankylosing Spondylitis and remains completed. Sponsored by Pfizer, it has been updated 27 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~May 2018 – ~Jul 2018 · 2 months · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Oct 2020 · 5 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Oct 2021 · 8 months · monthly snapshot~Oct 2021 – ~Jul 2024 · 33 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

27 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Oct 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Feb 2021 — Oct 2021 [monthly]

    Completed PHASE3

▶ Show 22 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE3

  2. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. May 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  4. Mar 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Nov 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  8. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  9. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  10. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  11. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  12. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  13. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  14. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  15. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  16. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  17. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  18. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  19. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  20. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  21. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  22. May 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ankara, Turkey (Türkiye) , Ashkelon, Israel , Bridgeport, United States , Budapest, Hungary , Camberwell, Australia , Colleyville, United States , Corpus Christi, United States , Covina, United States , Dallas, United States , Duncansville, United States and 59 more locations